Vitrectomy in proliferative diabetic retinopathy, the last 10 years

Article

Highlighting the evolving trends in surgical technique and the impact on disease management

This report aims to highlight the evolving trends in surgical management of this complex vitreoretinal disorder and provides some insight into current practice and evidence-based medicine. We will also report our own experiences and share 10 year anatomical and visual outcome in patients who underwent 20-gauge (20G) pars plana vitrectomy (PPV) for complications of PDR under the supervision of a single surgeon (THW) at a teaching hospital in south east London, UK.

Vitrectomy surgery

Smaller gauge transconjunctival sutureless vitrectomy offers theoretical advantages of shorter surgical time, less postoperative inflammation, faster visual recovery and improved patient comfort. But these benefits are balanced in complex vitreoretinal adhesion and fibrovascular proliferations - seen in PDR as a result of altered fluidics with reduced flow through the smaller probe as compared to 20G. Advances such as 25G ultra high speed PPV machinery9 that has better fluid dynamic control, high speed cutting rate (5000 cuts per minute) and viscodissection assisted microincision vitrectomy10 offer new options in microincision vitrectomy.

Anatomical and visual results following PPV in complications due to DR with different gauges of vitrectomy instrumentation are comparable. In a retrospective study of 101 eyes by Park et al.11 no beneficial effects on anatomical and visual outcome were seen after direct comparison between 20- and 23-G PPV. However, there were more cases of hypotony in the 23-G PPV group.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.